Factors Affecting the Recurrence and Survival of Hepatocellular Carcinoma After Hepatectomy: a Retrospective Study of 601 Chinese Patients

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2015 Nov 19

PMID 26577107

Citations 17

Authors

T T Zhang

X Q Zhao

Z Liu

Z Y Mao

L Bai

Affiliations

Soon will be listed here.

Abstract

Objective: Indications for resection of hepatocellular carcinoma (HCC) remain controversial. This study aimed to identify prognostic factors that affect overall survival (OS) and disease-free survival (DFS) in patients with HCC after hepatectomy.

Methods: From 2004 to 2010, 601 patients with HCC who underwent resection were enrolled. Factors stratified into the host, biochemical, surgical treatment and tumor-related features in terms of recurrence and overall survival were analyzed. Prognostic factors were evaluated by univariate and multivariate analyses, with Kaplan-Meier survival analyses and Cox proportional hazard model.

Results: The overall survival rates of 1-, 3- and 5- year were 79, 62, and 54 %, and the corresponding DFS rates were 51, 38 and 31 %, respectively. In a multivariate analysis, Child-Pugh, serum AFP level, ALT level, time for hepatic resection, tumor differentiation, maximum size of tumors, local necrosis, portal vein tumor thrombus, and TNM Stage were correlated significantly with patients' OS. Gender (P = 0.046), cigarette smoking (P = 0.007), serum AFP level (P = 0.001), GGT level (P = 0.002), maximum size of tumors (P = 0.009), liver cirrhosis (P = 0.025), portal vein tumor thrombus (P = 0.022), microvascular tumor thrombus (P = 0.007) and TNM Stage (P = 0.001) were significantly affected DFS.

Conclusion: Preoperative AFP level, maximum size of tumors, portal vein tumor thrombus and TNM Stage were revealed as important prognostic factors for OS and DFS through follow-up of a relatively large cohort of Chinese HCC patients.

Citing Articles

Development and validation of a prognostic nomogram to predict the recurrence of AFP-negative and DCP-positive hepatocellular carcinoma after curative resection.

Li J, Wang Q, Yan Y, Sun L, Zhang G, Li G Front Oncol. 2024; 14:1414083.

PMID: 39175473 PMC: 11338900. DOI: 10.3389/fonc.2024.1414083.

Which factors predict tumor recurrence and survival after curative hepatectomy in hepatocellular carcinoma? Results from a European institution.

Vaghiri S, Prassas D, Mustafov O, Kalmuk S, Knoefel W, Lehwald-Tywuschik N BMC Surg. 2024; 24(1):101.

PMID: 38589847 PMC: 11003056. DOI: 10.1186/s12893-024-02399-y.

Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.

Wang P, Wang X, Liu X, Yan F, Yan H, Zhou D BMC Cancer. 2023; 23(1):564.

PMID: 37340357 PMC: 10280839. DOI: 10.1186/s12885-023-11059-y.

Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.

Li Y, Zhao J, Yang C, Zhan G, Zhang J, Qin S PLoS Negl Trop Dis. 2023; 17(1):e0011012.

PMID: 36638133 PMC: 9879467. DOI: 10.1371/journal.pntd.0011012.

GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.

Du M, Feng J, Tao Y, Pan Q, Chen F J Healthc Eng. 2021; 2021:7631815.

PMID: 34900204 PMC: 8654523. DOI: 10.1155/2021/7631815.

References

Yamashita Y, Taketomi A, Shirabe K, Aishima S, Tsuijita E, Morita K . Outcomes of hepatic resection for huge hepatocellular carcinoma (≥ 10 cm in diameter). J Surg Oncol. 2011; 104(3):292-8. DOI: 10.1002/jso.21931. View

Hu L, Xue F, Li Y, Shao M, Sun Y, Wei G . A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma. Cell Biochem Biophys. 2014; 69(3):421-31. DOI: 10.1007/s12013-013-9813-3. View

Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E . Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg. 2011; 36(1):136-43. DOI: 10.1007/s00268-011-1317-y. View

Wang Y, Wang P, Wang B, Fu Z, Zhao W, Yan S . Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2014; 9(5):e95485. PMC: 4022589. DOI: 10.1371/journal.pone.0095485. View

Shih W, Chang H, Liaw Y, Lin S, Lee S, Chen P . Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer. 2012; 131(11):2612-21. DOI: 10.1002/ijc.27508. View

Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M . Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg. 2011; 98(4):552-7. DOI: 10.1002/bjs.7393. View

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N . Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008; 15(5):1375-82. DOI: 10.1245/s10434-008-9846-9. View

Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon A, Kamiyama Y . Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg. 2009; 198(1):39-45. DOI: 10.1016/j.amjsurg.2008.07.051. View

10.

Giovannucci E, Rimm E, Ascherio A, Colditz G, Spiegelman D, Stampfer M . Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev. 1999; 8(4 Pt 1):277-82. View

11.

Pawlik T, Delman K, Vauthey J, Nagorney D, Ng I, Ikai I . Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005; 11(9):1086-92. DOI: 10.1002/lt.20472. View

12.

Vitale A, Saracino E, Boccagni P, Brolese A, DAmico F, Gringeri E . Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc. 2009; 41(4):1260-3. DOI: 10.1016/j.transproceed.2009.03.054. View

13.

Zhou L, Rui J, Wang S, Chen S, Qu Q . Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis. Pathol Oncol Res. 2014; 21(1):131-8. DOI: 10.1007/s12253-014-9798-2. View

14.

Zhang J, Shu Z, Xie C, Li Q, Jin X, Gu W . Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014; 9(3):e88182. PMC: 3946426. DOI: 10.1371/journal.pone.0088182. View

15.

Ferenci P, Fried M, LaBrecque D, Bruix J, Sherman M, Omata M . Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010; 44(4):239-45. DOI: 10.1097/MCG.0b013e3181d46ef2. View

16.

Prieto J . Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol. 2007; 48(2):380-1. DOI: 10.1016/j.jhep.2007.11.007. View

17.

Allemann P, Demartines N, Bouzourene H, Tempia A, Halkic N . Long-term outcome after liver resection for hepatocellular carcinoma larger than 10 cm. World J Surg. 2012; 37(2):452-8. DOI: 10.1007/s00268-012-1840-5. View

18.

Zhang X, Wei T, Liu X, Liu C, Lv Y . Impact of cigarette smoking on outcome of hepatocellular carcinoma after surgery in patients with hepatitis B. PLoS One. 2014; 9(1):e85077. PMC: 3893178. DOI: 10.1371/journal.pone.0085077. View

19.

Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao Y . Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg. 2011; 203(6):741-50. DOI: 10.1016/j.amjsurg.2011.05.010. View

20.

Altamirano J, Bataller R . Cigarette smoking and chronic liver diseases. Gut. 2010; 59(9):1159-62. DOI: 10.1136/gut.2008.162453. View